Meeting
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness.
Authors
Tamara A. Sussman
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Tamara A. Sussman , Wei Wei , Brian Hobbs , C. Marcela Diaz-Montero , Ying Ni , Joshua Arbesman , Jennifer S. Ko , Brian Gastman , Pauline Funchain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04187833
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS10082)
DOI
10.1200/JCO.2020.38.15_suppl.TPS10082
Abstract #
TPS10082
Poster Bd #
431
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George
Poster
2023 ASCO Annual Meeting
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
First Author: Anup Kasi
Poster
2023 ASCO Annual Meeting
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).
First Author: Heidi Chwan Ko
Poster
2019 ASCO Annual Meeting
Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.
First Author: Anup Kasi